These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30470585)

  • 1. Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin.
    Müller-Arteaga C; Batista-Miranda JE; Zubiaur Libano C; El Khoury Moreno R; Morales Solchaga G; Casas Nebra J; Leva Vallejo M; Gonzalez Garcia O; Errando-Smet C; Arlandis-Guzman S
    Actas Urol Esp (Engl Ed); 2019 Apr; 43(3):143-150. PubMed ID: 30470585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
    Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
    J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of oxybutynin in transdermal patches for treating overactive bladder.
    Salinas-Casado J; Esteban-Fuertes M; Serrano O; Galván J
    Actas Urol Esp; 2015 Dec; 39(10):599-604. PubMed ID: 26321038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal drug delivery treatment for overactive bladder.
    Dmochowski RR; Starkman JS; Davila GW
    Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration.
    Gleason JM; Daniels C; Williams K; Varghese A; Koyle MA; Bägli DJ; Pippi Salle JL; Lorenzo AJ
    J Pediatr Urol; 2014 Aug; 10(4):753-7. PubMed ID: 24477421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
    Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV
    Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
    Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
    Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder-wet Patients over the Age of 75 Years with Mild Cognitive Impairment.
    Rajabali S; Asaana P; Nazari S; Wagg A
    Eur Urol Focus; 2024 Mar; 10(2):325-331. PubMed ID: 38402104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.
    Staskin DR; Rosenberg MT; Dahl NV; Polishuk PV; Zinner NR
    Int J Clin Pract; 2008 Jan; 62(1):27-38. PubMed ID: 17983434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution of transdermal therapy for overactive bladder.
    Sand PK
    Curr Urol Rep; 2009 Sep; 10(5):338-41. PubMed ID: 19709479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxybutynin gel for the treatment of overactive bladder.
    Gomelsky A; Dmochowski RR
    Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal oxybutynin.
    Baldwin CM; Keating GM
    Drugs; 2009; 69(3):327-37. PubMed ID: 19275276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study.
    Aaron LE; Morris TJ; Jahshan P; Reiz JL
    Curr Med Res Opin; 2012 Aug; 28(8):1369-79. PubMed ID: 22769237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial.
    Yokoyama O; Yamaguchi A; Yoshida M; Yamanishi T; Ishizuka O; Seki N; Takahashi S; Yamaguchi O; Higo N; Minami H; Masegi Y
    Int J Urol; 2015 Jul; 22(7):684-8. PubMed ID: 25782032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14.
    Cornel EB
    Eur Urol; 2007 Jul; 52(1):286-7; author reply 287. PubMed ID: 17434252
    [No Abstract]   [Full Text] [Related]  

  • 18. Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study.
    Yoo DS; Han JY; Lee KS; Choo MS
    Int J Clin Pract; 2012 Feb; 66(2):132-8. PubMed ID: 22188444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tolerability, persistence and satisfaction. Retrospective cohort study in patients with overactive bladder syndrome treated with transdermal Oxybutynin under Standard ClinicAl pRactice. OSCAR Study.].
    Vozmediano-Chicharro R; Blasco Hernández P; Madurga-Patuel B
    Arch Esp Urol; 2017 Jul; 70(6):561-569. PubMed ID: 28678009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
    Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
    Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.